Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 7/20 | 0.65 |
| ▸ | ACE | P12821 | 5/20 | 0.65 |
| ▸ | CPA1 | P15085 | 2/20 | 0.65 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.65 |
| ▸ | TACR1 | P25103 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.59 |
| ▸ | MMP9 | P14780 | 2/20 | 0.54 |
| ▸ | MMP8 | P22894 | 2/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | IL2 | P60568 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL607215 | 1.00 | MME (0.65) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL29386502 | 1.00 | MME (0.65) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL607214 | 1.00 | MME (0.65) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL29413287 | 0.92 | MME (0.65) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL23178150 | 0.88 | MME (0.60) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL30712864 | 0.88 | MME (0.60) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL30712855 | 0.88 | MME (0.60) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL15342313 | 0.88 | MME (0.60) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL29386041 | 0.88 | MME (0.60) | MMEACECPA1ACE2TACR1 | |
| SCHEMBL22788735 | 0.87 | TACR1 (0.62) | MMEACECPA1ACE2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034192-A1 | USE OF GNRH ANTAGONISTS IN MAMMALS TO SYNCHRONIZE FOLLICULAR WAVE EMERGENCE | UNIV SASKATCHEWAN (CA) | 2026-02-05 | — | — | US | disclosed |
| EP-4558159-A1 | USE OF GNRH ANTAGONISTS IN MAMMALS TO SYNCHRONIZE FOLLICULAR WAVE EMERGENCE | University of Saskatchewan (CA) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024016072-A1 | USE OF GNRH ANTAGONISTS IN MAMMALS TO SYNCHRONIZE FOLLICULAR WAVE EMERGENCE | UNIVERSITY OF SASKATCHEWAN (CA) | 2024-01-25 | — | — | WO | disclosed |
| US-20210094983-A1 | MODIFIED PEPTIDES FOR USE IN TREATING NEURODEGENERATIVE DISORDERS | NEURO-BIO LTD. (GB) | 2021-04-01 | — | — | US | disclosed |
| CN-102947332-A | Novel octapeptide compounds and therapeutic use thereof | IPSEN PHARMA SAS | 2013-02-27 | — | — | CN | disclosed |
| US-5767082-A | ANTIFERTILITY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-4801577-A | REPRODUCTION CONTROL | SYNTEX (U.S.A.) INC. (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0097031-B1 | NONAPEPTIDE AND DECAPEPTIDE ANALOGS OF LHRH USEFUL AS LHRH ANTAGONISTS, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1988-09-21 | — | — | EP | disclosed |
| US-4581169-A | Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1986-04-08 | — | — | US | disclosed |
| EP-0049628-B1 | NONAPEPTIDE AND DECAPEPTIDE ANALOGS OF LHRH, USEFUL AS LHRH ANTAGONISTS, METHODS OF MAKING THEM, AND THEIR PHARMACEUTICAL USES | SYNTEX (U.S.A.) INC. (US) | 1985-07-03 | — | — | EP | disclosed |
| US-4481190-A | LUTEINIZING HORMONE RELEASING HORMONE | SYNTEX (U.S.A.) INC. (US) | 1984-11-06 | — | — | US | disclosed |
| EP-0021234-B1 | NONAPEPTIDE AND DECAPEPTIDE DERIVATIVES OF LUTEINIZING HORMONE RELEASING HORMONE, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1984-08-22 | — | — | EP | disclosed |
| EP-0097031-A2 | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists, their preparation and compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1983-12-28 | — | — | EP | disclosed |
| US-4419347-A | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1983-12-06 | — | — | US | disclosed |
| US-4341767-A | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists | SYNTEX INC. (US) | 1982-07-27 | — | — | US | disclosed |
| EP-0049628-A2 | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists, methods of making them, and their pharmaceutical uses | SYNTEX (U.S.A.) INC. (US) | 1982-04-14 | — | — | EP | disclosed |
| EP-0021234-A1 | Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone, their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4234571-A | CONTRACEPTIVES, ANTIFERTILITY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094983-A1 | MODIFIED PEPTIDES FOR USE IN TREATING NEURODEGENERATIVE DISORDERS | IAPP, NLN, APP | MME 27/4885ACE 1434/4885CPA1 773/4885 |
| US-20260034192-A1 | USE OF GNRH ANTAGONISTS IN MAMMALS TO SYNCHRONIZE FOLLICULAR WAVE EMERGENCE | GNRHR, FSHR, PGF | MME 177/4885ACE 1173/4885CPA1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.